Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Recruiting

Phase 2

NVG-2089Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Sponsor:

Nuvig Therapeutics, Inc.

Code:

NCT07027111

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NVG-2089

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-20. This information was provided to ClinicalTrials.gov by Nuvig Therapeutics, Inc. on 2025-06-18.